Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab and Venetoclax in Untreated Follicular Lymphoma
NCT02877550Phase 1Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Feb 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax in follicular lymphoma (FL), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Dose Limiting Toxicities. Started Feb 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02877550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877550.